Aegis Reiterates Buy Rating for CytRx (CYTR)
CytRx (NASDAQ:CYTR)‘s stock had its “buy” rating reaffirmed by research analysts at Aegis in a report released on Monday, American Banking & Market News reports.
Shares of CytRx (NASDAQ:CYTR) traded up 4.66% during mid-day trading on Monday, hitting $3.37. 2,388,182 shares of the company’s stock traded hands. CytRx has a 52-week low of $1.95 and a 52-week high of $8.35. The stock’s 50-day moving average is $3.46 and its 200-day moving average is $4.34. The company’s market cap is $188.0 million.
CytRx (NASDAQ:CYTR) last released its earnings data on Thursday, May 1st. The company reported $0.09 earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.18) by $0.27. Analysts expect that CytRx will post $-0.60 EPS for the current fiscal year.
CytRx Corporation as (NASDAQ:CYTR) is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, specializing in oncology.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.